Prosecution Insights
Last updated: August 16, 2026

University Health Network

29 pending office actions • 18 art units • 24 examiners • 0 of 29 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days

Portfolio Summary

29
Total Pending OAs
17
Non-Final OAs
11
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
5
Due this month
2
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (5)Due ≤ 60 days (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

15
Hard (52%)
10
Medium (34%)
3
Easy (10%)
1
Unknown (3%)

Rejection Statute Mix

BucketCases
§101 + other6 (21%)
§103 only6 (21%)
§112 only1 (3%)
Double-patenting only2 (7%)
Double-patenting + other4 (14%)
Multi-statute (no §101)9 (31%)
No statute on record1 (3%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

18
Life Sciences
62% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
8
Mechanical / Eng
28% of docket
3
Business / Other
10% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

290 h
Manual time on pending OAs
58 h
Time saved (low, 20%)
102 h
Time saved (mid, 35%)
2.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AKAR, SERKAN 4 65.7% +33.4%
NGUYEN, NGHI V 2 53.4% +50.7%
D' AMBROSIO, THEA 2 55.8% +56.5%
NEWTON, CHAD A 1 38.0% +25.0%
CHNG, JOY POH AI 1 60.7% +18.7%
SHIAO, REI TSANG 1 79.8% -33.7%
MOSS, NATALIE M 1 30.9% +16.7%
FONTAINHAS, AURORA M 1 38.0% +49.1%
MOSHER, ERIC PARKER 1 100.0% +0.0%
UNDERDAHL, THANE E 1 58.9% +50.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18578888 PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE MOSHER, ERIC PARKER

Hard Cases (15)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18235679 COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE MERTZ, PREMA MARIA 24d overdue
19024995 PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING AKAR, SERKAN 8d overdue
18008053 IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY JOHANNSEN, DIANA B 4d overdue
17924040 METHODS AND COMPOSITIONS FOR MAKING AND USING ENDOCARDIAL CELLS ROGERS, ERIC JASON 21d
17631820 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF D' AMBROSIO, THEA 22d
17620103 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE CHENG, KAREN 23d
18908568 SYSTEM AND METHOD FOR REMOTE PATIENT MONITORING NEWTON, CHAD A 34d
18034278 FIXATIVE COMPOSITIONS AND METHODS OF PRESERVING BIOLOGICAL SAMPLES NGUYEN, NGHI V 42d

Interview Candidates (13)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
19024995 PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING AKAR, SERKAN 8d overdue
18441770 ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE ON DONOR ORGANS, METHODS AND USES ASSOCIATED THEREWITH MOSS, NATALIE M 4d overdue
17631820 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF D' AMBROSIO, THEA 22d
18908568 SYSTEM AND METHOD FOR REMOTE PATIENT MONITORING NEWTON, CHAD A 34d
18034278 FIXATIVE COMPOSITIONS AND METHODS OF PRESERVING BIOLOGICAL SAMPLES NGUYEN, NGHI V 42d
19025446 PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING AKAR, SERKAN 82d
19081680 METHOD AND SYSTEM FOR FLUORESCENCE IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES AKAR, SERKAN
18899233 NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE CHNG, JOY POH AI

Top Art Units

Art UnitApps
3797 4
1653 3
1682 2
1675 2
1654 2
3681 1
3686 1
1699 1
1674 1
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19081680 METHOD AND SYSTEM FOR FLUORESCENCE IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES AKAR, SERKAN 3797 §103 Non-Final OA Pending Mar 17, 2025
19025446 PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING AKAR, SERKAN 3797 DP Final Rejection 82d Pending Jan 16, 2025
19024995 PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING AKAR, SERKAN 3797 §103§112 Non-Final OA 8d overdue Pending Jan 16, 2025
18908568 SYSTEM AND METHOD FOR REMOTE PATIENT MONITORING NEWTON, CHAD A 3681 §101§103 Final Rejection 34d Pending Oct 07, 2024
18899233 NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE CHNG, JOY POH AI 3686 §101§112 Non-Final OA Pending Sep 27, 2024
18723094 TREATMENT FOR ACUTE MYELOID LEUKEMIA OR LYMPHOMA SHIAO, REI TSANG DP Non-Final OA Pending Jun 21, 2024
18441770 ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE ON DONOR ORGANS, METHODS AND USES ASSOCIATED THEREWITH MOSS, NATALIE M 1653 §103 Final Rejection 4d overdue Pending Feb 14, 2024
18414178 ANTI-TRANSTHYRETIN ANTIBODIES FONTAINHAS, AURORA M §112DP Non-Final OA Pending Jan 16, 2024
18578888 PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE MOSHER, ERIC PARKER §103§112DP Non-Final OA Pending Jan 12, 2024
18569063 CARDIOMYOCYTE SUBTYPES AND METHODS OF MAKING AND USING UNDERDAHL, THANE E 1699 §101§102§103DPOther Non-Final OA Pending Dec 11, 2023
18235679 COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE MERTZ, PREMA MARIA 1674 §103§112 Non-Final OA 24d overdue Pending Aug 18, 2023
18263658 IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS JUEDES, AMY E 1644 §102§103§112 Non-Final OA Pending Jul 31, 2023
17916981 COMPOSITIONS AND METHODS FOR ENHANCING ACTIVATION AND CYTOLYTIC ACTIVITY OF CD8+ T CELLS THROUGH DISRUPTION OF THE SAGA (SPT-ADA-GCN5-ACETYLTRANSFERASE) COMPLEX SU-TOBON, QIWEN NMN 1636 §112DP Non-Final OA Pending Jul 13, 2023
18210490 CRITICAL QUALITY ATTRIBUTES FOR IDENTIFYING MESENCHYMAL STROMAL CELLS WITH IMMUNOMODULATORY AND ANGIOGENIC FITNESS AUGER, NOAH ANDREW 1682 §101§103§112 Non-Final OA Pending Jun 15, 2023
18034278 FIXATIVE COMPOSITIONS AND METHODS OF PRESERVING BIOLOGICAL SAMPLES NGUYEN, NGHI V 1653 §103§112 Non-Final OA 42d Pending Apr 27, 2023
18023289 COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS STAVROU, CONSTANTINA E 1632 §103 Final Rejection 31d overdue Pending Feb 24, 2023
18008053 IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY JOHANNSEN, DIANA B 1682 §101§102§103§112 Non-Final OA 4d overdue Pending Dec 02, 2022
17924040 METHODS AND COMPOSITIONS FOR MAKING AND USING ENDOCARDIAL CELLS ROGERS, ERIC JASON 1638 §102§103§112Other Non-Final OA 21d Pending Nov 08, 2022
17915086 METHODS, COMPOSITIONS, AND SYSTEMS FOR ENHANCING EX-VIVO ORGAN PERFUSION NGUYEN, NGHI V 1653 §103 Final Rejection Pending Sep 27, 2022
17911208 BIOMARKERS FOR DETECTING OF OUTCOME/RISK OF THE PATIENTS WITH A RESPIRATORY ILLNESS CHERNYSHEV, OLGA N 1675 §101§112 Final Rejection Pending Sep 13, 2022
17744483 SCREW-IN BIPOLAR ABLATION, MAPPING AND THERAPEUTIC CATHETER HADDAD, MOUSSA MAHER 3796 §103 Final Rejection 22d Pending May 13, 2022
17631820 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF D' AMBROSIO, THEA 1654 §103§112Other Non-Final OA 22d Pending Jan 31, 2022
17631818 METHODS OF IDENTIFYING T CELL RECEPTORS DIBRINO, MARIANNE 1641 §102§112Other Final Rejection Pending Jan 31, 2022
17631824 MHC CLASS II MOLECULES AND METHODS OF USE THEREOF D' AMBROSIO, THEA 1654 Other Non-Final OA Pending Jan 31, 2022
17620103 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE CHENG, KAREN 1623 §102§103 Final Rejection 23d Pending Dec 16, 2021
17616522 METHODS OF MAKING AND USING LIVER CELLS RAHMAN, MASUDUR 1633 §112 Non-Final OA Pending Dec 03, 2021
17509914 METHOD AND SYSTEM FOR IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES AKAR, SERKAN 3797 §103§112 Non-Final OA Pending Oct 25, 2021
17413772 BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE BORGEEST, CHRISTINA M 1675 §112DP Final Rejection Pending Jun 14, 2021
16966293 DEVICES, SYSTEMS, AND METHODS FOR TUMOR VISUALIZATION AND REMOVAL TRUONG, MILTON LARSON 3798 §103 Final Rejection 29d Pending Jul 30, 2020

Managing University Health Network's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month